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2Abstract  
Context. Post-finasteride syndrome (PFS) occurs in patients with androgenic alopecia after 
suspension of the finasteride treatment, leading to a large variety of persistent side effects. 
Despite the severity of the clinical picture, the mechanism underlying the PFS symptoms 
onset and persistence is still unclear.
Objective. To study whether epigenetic modifications occur in PFS patients.
Methods. Retrospective analysis of a multicentric, prospective, longitudinal, case-control 
clinical trial, enrolling 16 PFS patients, compared to 20 age-matched healthy men. Main 
outcomes were methylation pattern of SRD5A1 and SRD5A2 promoters and concentration 
of eleven neuroactive steroids, measured by liquid chromatography-tandem mass 
spectrometry, in blood and cerebrospinal fluid (CSF) samples. 
Results. SRD5A1 and SRD5A2 methylation analysis was performed in all blood samples 
(n=16 PFS patients and n=20 controls), in 16 CSF samples from PFS patients and in 13 
CSF samples from controls. The SRD5A2 promoter was more frequently methylated in 
CSF of PFS patients compared to controls (56.3 versus 7.7%). No promoter methylation 
was detected in blood samples in both groups. No methylation occurred in the SRD5A1 
promoter of both groups. Unmethylated controls compared to unmethylated SRD5A2 
patients showed higher pregnenolone, dihydrotestosterone and dihydroprogesterone, 
together with lower testosterone CSF levels. Andrological and neurological assessments 
did not differ between methylated and unmethylated subjects.
Conclusions. For the first time, we demonstrate a tissue-specific methylation pattern of 
SRD5A2 promoter in PFS patients. Although we cannot conclude whether this pattern is 
prenatally established or induced by finasteride treatment, it could represent an important 
mechanism of neuroactive steroid levels and behavioural disturbances previously 
described in PFS.
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4Introduction
Finasteride is an inhibitor of 5alpha-reductase (5α-R) type 1 and 2 enzymes, encoded by 
the SRD5A1 and SRD5A2 gene, respectively, with higher affinity for 5α-R type 2 in the 
human [1, 2]. This enzyme converts testosterone (T) into dihydrotestosterone (DHT) and 
progesterone into dihydroprogesterone (DHP) [3]. 
Clinically, finasteride is used to control the progression of benign prostatic hyperplasia and 
of androgenetic alopecia. Albeit being a well-tolerated and relatively safe drug, recent 
clinical studies showed sexual adverse effects [2, 4-7]. Interestingly, a small subset of 
patients using finasteride for androgenic alopecia, complains of persistent sexual side 
effects during and even after discontinuation of the treatment [2, 8-20]. Beside adverse 
events in the sexual sphere, some patients interrupting the treatment by finasteride 
develop depression [16-18, 20-23], reduction in self-confidence, decreased initiative and 
difficulty in concentration, forgetfulness or loss of short-term memory, irritability, suicidal 
thoughts, anxiety, panic attack, sleep problems, muscular stiffness and cramps, tremors, 
chronic fatigue, joint pain and muscular ache [18, 24-26]. These various symptoms amount 
to the so-called post-finasteride syndrome (PFS). Two recent clinical studies objectivated 
impaired sexual function and major depression in PSF patients [17, 18]. In addition, 
functional magnetic resonance imaging (MRI) showed abnormalities in the brain regions 
implicated in depression and regulating sexual arousal [17], and some evidence of 
neuropathy involving the peripheral neurogenic control of erection were produced [18]. 
PFS etiopathogenesis remains elusive. Three different clinical studies [18, 25, 26] 
demonstrated that finasteride treatment not only affects the steroids directly related with 
the enzyme 5α-R but has broad consequences on the levels of several important 
physiological regulators of the nervous function, such as neuroactive steroids, both in 
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of PFS, showing that alterations in the levels of neuroactive steroids not only occurred in 
plasma and CSF but also in brain areas, such as cerebral cortex, cerebellum and 
hippocampus [27], associated to depressive-like behavior, alterations in neurogenesis, 
gliosis, neuroinflammation and gut microbiota composition [28]. A possible hypothesis for 
the persistent side effects may be epigenetic modifications occurring in PFS patients. 
Indeed, downregulation and hypermethylation of 5α-R were observed in the rodent 
nervous system and associated with inflammation and depression [29, 30], features that, 
as mentioned above, have been also observed in PFS model [28]. In this setting, the 
evaluation of the methylation pattern remains challenging since it could change during 
adulthood and with aging [31].
In this study, we hypothesized that inappropriate methylation of SRD5A1 and/or SRD5A2 
gene promoters could be present in the central nervous system (CNS) of patients with 
PFS. No studies evaluated so far the methylation levels of these genes in a clinical setting. 
We compared SRD5A1 and/or SRD5A2 promoter methylation in DNA samples obtained 
from blood and/or CSF in PFS patients and controls, and correlated the resulting 
epigenetic pattern with the neuroactive steroids levels previously found by us to be 
associated with major depression and sexual side-effects [18].
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Study design and sample preparation
Sixteen patients affected by PFS, recruited through the “Italian network of finasteride side 
effects”, were included in this study. They were otherwise healthy men, aged 22-44 years, 
who reported persistent sexual and mental health side effects after the use of 1-1.25 mg of 
finasteride daily (Propecia, Proscar or generic finasteride) for androgenetic alopecia. Only 
subjects who had discontinued finasteride at least 3 months earlier were included. The 
study procedure was approved by the Ethics Committee of the San Gerardo Hospital 
(approval n.142/2012), Monza-Italy and the participating subjects provided their written 
informed consent before enrolment. This group of PFS patients was previously studied for 
psychiatric components, andrological assessment and neuroactive steroid levels in plasma 
and CSF [18].
PFS patients underwent both blood and CSF sampling for SRDA51 and SRDA52 gene 
promoter methylation analysis. The control group included eighteen healthy individuals 
who underwent spinal anaesthesia for planned orthopaedic surgery of the lower limb at the 
San Gerardo Hospital of Monza. These subjects were otherwise healthy and never made 
used of finasteride. After written informed consent, CSF samples were collected. Two 
subjects of this group provided also a blood sample for DNA analysis. Moreover, the 
control group included additional eighteen age-matched healthy donors, who provided only 
blood samples for DNA analysis. Control subjects never used finasteride. The mean age of 
healthy controls (40.8 + 17.9 years) was not significantly different from PFS patients (34.5 
+ 8.8 years) (p=0.192).
SRD5A1 and SRD5A2 promoter sequences
Sequences of SRD5A1 and SRD5A2 gene promoters served for designing primer probes 
to be used for methylation analysis. SRD5A1 and SRD5A2 promoter sequences were 
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7obtained by the online Eukaryotic Promoter Database (EPD; http://epd.vital-it.ch) and 
correspond to the database ID “SRD5A1_1” and “SRD5A2_1”, respectively. The SRD5A2 
promoter sequence was previously described [32] and matched to that obtained by the 
EPD, confirming its reliability.
DNA extraction and Methylation analysis 
Genomic DNA was isolated from blood and CSF samples by the automated extractor EZ1 
Advanced XL (Qiagen, Hilden, Germany) using by the EZ1 DNA Blood and the EZ1 DNA 
Investigator Kits, respectively. We assumed that ependymal cells, of neuroectodermic 
origin and collected from CSF, are representative of the CNS, providing a source of 
genomic DNA without resorting to major clinical interventions. Due to the paucity of the 
cellular component in the CSF, DNA extraction was preliminarily validated, using a kit 
optimized for forensic purposes, to provide a yield of at least 2.8 ± 1.1 ng/µl from 4.3 ± 3.3 
cells/µl (data obtained from four random, anonymized, sterile CSF validation samples, 
ranging from 100 to 500 µl of total volume).
DNA concentrations and purity were determined by the NanoDrop™ 2000 
spectrophotometer (Thermo Fisher Scientific, San Jose, CA, USA), while the methylation 
pattern was analysed using the Human Methylated & Non-methylated DNA Set (Zimo 
Research, Irvine, CA, USA). Serial dilutions of methylated DNA (0-100% range), provided 
by the supplier, were performed to generate the standard curve. Deamination of cytosines 
was obtained by bisulfite-conversion of equal amounts of DNAs using the Methylamp DNA 
Modification Kit (EpiGentek, Farmingdale, NY, USA) and following the instructions 
provided by the Company. Quantitative methylation-specific polymerase chain reaction (Q-
MSP) was performed for methylation analysis of CpG islands of SRD5A1 and SRD5A2 
promoter regions. The methylation-specific primer pairs were designed by the 
MethPrimers Software [33] as follow: SRD5A1 forward (Fwd): 5’-
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8AGTTTTATATTTTTCGGGATTTTCG-3’ and reverse (Rev): 5’-
CGCTTTAAACTTATTCCTAAACGAT-3’; SRD5A2 Fwd: 5’-
AAGTTATGGAAGGATAGTTTAAGCG-3’ and Rev: 5’-TCTCAAAAATACAACCGCGAT-3’. 
The methylation-specific primers for the ACTB gene were previously validated [34] and 
used to provide the internal control. Reactions were performed using the Precision Melt 
Supermix (Bio-Rad Laboratories Inc., Hercules, CA, USA) following the supplier’s 
instructions and following settings: double-strand DNAs were pre-denatured 2-min at 95°C 
before 50 cycles of DNA denaturation at 95°C for 10 s, each followed by primer binding at 
59°C for 30 s and extension at 72°C for 30 s. Samples and the standard curve were 
analysed in duplicate and the percentage of DNA methylation was calculated using the 
previously described 2-ΔΔCt method [35] optimized for DNA methylation analyses [36, 37]. 
Briefly, ΔCt values were calculated by subtracting the internal control Ct value to Ct of 
samples and standards. ΔΔCt was determined by subtracting the ΔCt of the 100% 
methylated DNA standard to the ΔCt of samples and standard dilutions. Standards were 
plotted on a X-Y graph, where the percentage of methylated DNA is at the X axis while the 
2-ΔΔCt value is at the Y axis. These data were interpolated by linear regression and used 
for extrapolating the percentage of sample DNA methylation. 
Precision of the DNA methylation assay
Precision of the method was assessed by evaluating the coefficient of variation (%CV) [38] 
in relationship to the percentage of methylation. To this purpose, DNA with known 
percentages of methylation were created by serial dilution as reference standard and the 
coefficient of variation was calculated as the standard deviation divided by the mean 
(x100).
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were considered as unmethylated DNA, as previously proposed [39]. %CV of each sample 
was extrapolated from the reference standard curve and used for evaluating whether it 
was reliably determined as falling above the methylation cut-off value. All samples are 
reliably classified as “methylated” or “unmethylated”, according to the cut-off value fixed at 
10% CV. 
Statistical analysis
Results are expressed as mean ± SD. Methylation status of the SRD5A1 and SRD5A2 
gene promoters were expressed as percentage of methylated DNA extrapolated from the 
standard curve.
Kolmogorov-Smirnov test was used to evaluate continuous neuroactive steroid data 
distribution. Neuroactive steroid levels in plasma and CSF previously obtained [18] were 
compared between SRD5A2 unmethylated controls, methylated and unmethylated PFS 
patients using Kruskall-Wallis test followed by post-hoc Dunnet test. The correlation 
between neuroactive steroid levels and percentage of promoter gene methylation was 
evaluated using Spearman’s Rho test.
The degree of erectile dysfunction and the depressive status of PSF patients was 
previously reported [18] and was reassessed here by comparing SRD5A2 unmethylated 
and methylated PFS patients using Pearson’s chi-squared test. Similarly, the total score of 
Beck Depression and Anxiety Inventories (BDI, BAI) and K-10 was compared between 
patients with and without SRD5A2 methylation, using Mann-Whitney’s U-test.
Statistics was performed using ‘Statistical Package for the Social Sciences’ software for 
Macintosh (version 20.0; SPSS Inc., Chicago, IL). 
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Results
DNA methylation analysis of SRD5A1 and SRD5A2 was successfully performed in all 
blood samples (n=16 PFS patients and n= 20 controls), in 16 CSF samples from PFS 
patients and in 13 CSF samples from controls. 
The SRD5A1 gene promoter was completely unmethylated in all samples analysed, 
irrespective whether blood- or CSF-derived DNA. 
Similarly, the SRD5A2 gene promoter resulted unmethylated (i.e. methylation level <10%) 
in all blood-derived DNA samples, both in controls and in PFS patients. In CSF-derived 
DNA, the SRD5A2 gene promoter resulted methylated in 9 out of 16 PFS patients and in 1 
out of 13 controls (p=0.006, Pearson’s chi-square test, Table 1). Interestingly, the control 
subject with positive CSF SRD5A2 methylation was a man affected by normotensive 
hydrocephalus. In the PFS patients with positive SRD5A2 methylation in CSF, the 
methylation levels ranged from 15.4 to 100% (mean: 40.3%, median: 31.8%), while the 
unique control sample resulted to be positive to the test showed 58.0% methylation.
Neuroactive steroid levels in these subjects were reported previously [18]. In order to 
assess whether SRD5A2 methylation affects neuroactive steroid levels, here we compared 
CSF concentrations in unmethylated controls vs. unmethylated and methylated PFS 
patients (Table 2). Within the limits of the low subject number and of the sensitivity of the 
LC-MS/MS method for some analytes, the results showed some statistically significant 
differences (Table 2) indicating higher pregnenolone in unmethylated SRD5A2 controls vs. 
unmethylated SRD5A2 PFS patients. On the contrary, higher T levels were reported in 
unmethylated SRD5A2 PFS patients vs. unmethylated SRD5A2 controls.  The 5α-reduced 
metabolites of testosterone and progesterone were also affected. In particular, higher DHT 
levels were observed in unmethylated SRD5A2 controls vs. unmethylated SRD5A2 PFS 
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patients (Table 2). In addition, DHP levels were significantly higher in unmethylated 
SRD5A2 controls not only vs. unmethylated SRD5A2 PSF patients but also vs. methylated 
SRD5A2 PSF patients (Table 2). 
In PFS patients, neuroactive steroid CSF levels were not significantly related to the 
percentage of SRD5A2 gene promoter methylation (p>0.05, Spearman’s Rho test).
We next evaluated whether the clinical parameters reported earlier [18] were related to the 
SRD5A2 methylation status. No differences were observed in the degree of erectile 
dysfunction (p=0.362, Pearson's chi-square test). Accordingly, the five international 
indexes of erectile function (IIEF-15) domains, identified as erectile function, orgasm, 
sexual desire, intercourse satisfaction and overall satisfaction, did not differ between 
groups (p=0.710, p=0.456, p=0.535, p=0.805 and p=0.620, respectively). Similarly, the 
depressive status previously demonstrated in these PFS patients [18] did not change 
between SRD5A2 methylated and unmethylated subjects, considering K-10 (p=0.890) and 
BDI and BAI (p=0.475 and p=0,485, respectively). The depression and anxiety degree 
frequency did not change between two groups (p=0.270 and p=0.176, respectively).
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Discussion
In this study we demonstrate that SRD5A2 promoter methylation in PFS patients is 
different between tissues of neuroectodermic and mesodermic origin Although DNA 
extraction was insufficient in five CSF samples, a significant difference between PFS 
patients and controls in SRD5A2 promoter methylation of nervous system (i.e., in CSF) 
was demonstrated, while no differences were seen for the SRD5A1 gene, which resulted 
unmethylated in all samples analysed. Interestingly, in PFS patients, SRD5A2 methylation 
was detected in CSF DNA samples in 56% of the cases while it was absent in blood DNA, 
demonstrating a tissue-specific epigenetic gene silencing. The only CSF sample showing 
SRD5A2 methylation in controls was detected in one man with normotensive 
hydrocephalus. Methylation in CSF but not in blood may be not surprising, since 
methylation is a tissue- and cell-specific process [40-42]. The low number of cases studied 
here does not allow definitive conclusions, but we can speculate that PFS primarily affects 
nervous system via methylation of SRD5A2, which, in turn, may be related to the clinical 
picture of PFS patients (i.e., major depression and evidence of neuropathy involving the 
peripheral neurogenic control of erection) [18, 43]. 
In this context, it is important to note that in human prostate, methylation of SRD5A2 is 
regulated by DNA methyltransferase 1 (DNMT1) [44] and that, as demonstrated in animal 
models, forebrain deletion of DNMT1 [45] or its pharmacological inhibition [44, 46] had 
antidepressant-like properties.
The reason for the persistence of PFS symptoms even long after drug withdrawal in PFS 
patients remains a mystery. The molecular mechanism of 5α-R inactivation by finasteride 
is known since two decades [47], likely resulting in persistent enzymatic inhibition over 
time [47, 48], but this does not fully justify the long-lasting alteration of the neuroactive 
steroid levels, unless several months/years are required to completely wash-out the drug 
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from the CSF. Assuming that the 5α-R protein blocked by finasteride cannot become 
functional again, in this study we hypothesized that new SRD5A1 and SRD5A2 transcripts 
should be produced and new 5α-R protein should be available once the drug is 
interrupted, provided the gene promoters are not methylated and silenced. This should be 
evident from the CSF steroid concentrations in relation to the methylation pattern. 
Significant changes in neuroactive steroid levels in this group of PFS patients were 
published earlier, demonstrating a derangement of these levels upstream T production 
[18]. In fact, PFS patients showed higher serum and CSF T levels than healthy controls, 
while other neuroactive steroids, also including DHT, were suppressed [18]. In the present 
study, the comparison of CSF steroid levels subdividing the patients according to their 
SRD5A2 methylation status provided some further insights. In unmethylated SRD5A2 PFS 
patients we can assume that type 2 5α-R is regularly expressed in CNS and finasteride 
can act on it. Indeed, in these patients the blockade of 5α-R activity by finasteride results 
in significant accumulation of T and significant reduction of 5α-reduced metabolites DHT 
and DHP, the latter being even undetectable (Table 2). On the other hand, in methylated 
SRD5A2 patients, finasteride might act, even if with lower affinity, predominantly or only on 
the type 1 5α-R, since SRD5A1 should be expressed. This is suggested by the only partial 
reduction of DHP, while T and DHT levels were not significantly different from controls. 
The significant decrease in pregnenolone in SRD5A2 unmethylated PFS patients 
compared to controls indicate that the blockade of type 2 5α-R activity impacts the very 
early steps of neurosteroidogenesis as well, although with unknown mechanism. These 
results, however, must be interpreted with extreme caution, given the low number of 
subjects analysed. In animal models it was demonstrated that neurosteroidogenesis may 
proceed in the brain converting progesterone in DHP and further into 
tetrahydroprogesterone (THP; allopregnanolone) [3] via a pathway similar to the so-called 
backdoor pathway of 5α-reduction, using type 1 5α-R [49]. Therefore, the changes in 
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neuroactive steroid levels in CSF of PFS patients demonstrated earlier [18], might be due 
to inhibition of type 2 5α-R only in the subjects with unmethylated SRD5A2, while in those 
with methylated SRD5A2, type 1 5α-R could be the target of finasteride. Whether the 
sexual and psychiatric symptoms documented in these patients are related to methylation 
of SRD5A2 cannot be concluded by this study, as no significant differences could be 
demonstrated in dependence thereof, probably due to the low number of subjects. 
Presently it is impossible to establish whether the SRD5A2 methylation pattern in PFS 
patients is set during early embryo development or results from finasteride treatment itself. 
DNA methylation is imprinted during gamete production and reprogrammed before embryo 
implantation [50]. Besides the role in determining tissue-specific gene expression, 
epigenetic mechanisms regulate the individual-specific differentiation of pluripotent stem 
cells into neurons, suggesting that methylation impacts the pathogenesis of psychiatric 
disorders [51]. Recent findings in rat models confirmed that altered epigenetic processes, 
consisting in abnormal DNA methyltransferase protein levels and increased global DNA 
methylation levels, are linked to anxiety- and depression-like behaviour [52]. Our finding of 
high levels of methylated SRD5A2 in CNS cells of a normotensive hydrocephalus 
individual, displaying an epigenetic status at odds with all other control subjects, further 
supports the link between DNA methylation pattern and disorders of the nervous system 
[53]. If abnormal SRD5A2 promoter methylation is established prenatally, these subjects 
could be predisposed to develop the PFS and alteration of neuroactive steroid levels in the 
brain. In this case, treatment by finasteride might precipitate a dormant depressive 
phenotype linked to such specific epigenetic pattern, resulting in the clinical picture 
described previously [18, 43]. Before finasteride treatment, the impairment of 5α-R type 2 
in the nervous system would be partly compensated by the activity of the 5α-R type 1, 
found always unmethylated and thereby expressed. On the other hand, the native DNA 
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methylation pattern may change during adulthood and it is susceptible to ageing [54, 55], 
diseases [56-59], environmental factors and inflammation [60, 61]. Most importantly, 
similar effects might be triggered by prolonged exposure to certain drugs, such as 
amphetamine and methamphetamine [62], inducing behavioural abnormalities. We cannot 
exclude that some SRD5A2 promoter methylation is determined by finasteride (or other 
drugs) exposure in adulthood in some subjects developing PFS, although the mechanism 
of such predisposition remains obscure. Given that epigenetic programming impacts the 
neuroendocrine response during the adult life [63], we could hypothesize that finasteride 
impairs DNA methylation targeted to the nervous system, leading to altered neurosteroid 
CSF levels and leading to major depression and neuropathy described in PFS patients 
[18, 43], but this remains highly speculative.
In conclusion, our results demonstrate methylation of SRD5A2 promoter in a tissue-
specific manner in PFS patients. Whether this epigenetic pattern is established prenatally 
or induced by finasteride treatment cannot be concluded but this study pinpoints the 
relevance of this specific methylation pattern and its correlation with levels of neuroactive 
steroids and their effects [18, 43]. Animal models might be useful to elucidate the link 
between the use of finasteride, epigenetic changes, neuroactive steroid levels and 
behavioural disturbances described previously in PFS patients [27, 28].
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Table 1- SRD5A2 promoter methylation in DNA extracted from
cerebrospinal fluid of PFS patients and controls. 
Controls
(n)
PFS Patients
(n)
Total
(n)
Unmethylated SRD5A2 12 (92.3%) 7 (43.7%) 19
Methylated SRD5A2 1 (7.7%) 9 (56.3%) 10
Total (n) 13 16
Data were evaluated by Pearson’s Chi-square test, p < 0.01.
Page 24 of 25Accepted Manuscript published as EC-19-0199.R1. Accepted for publication: 04-Jul-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 07/05/2019 08:07:46AM
via Univ Modena e Reggio Emilia
Table 2. Neuroactive steroid CSF levels in patients and controls according to the SRD5A2 
methylation status.
Unmethylated
SRD5A2 
Controls
(n = 12)
Unmethylated 
SRD5A2
PFS patients
(n=7)
Methylated 
SRD5A2
PFS patients
(n=9)
p-
value
Pregnenolone 0.39 ± 0.25 0.09 ± 0.05* 0.31 ± 0.46 0.008
Progesterone 0.11 ± 0.14 0.05 ± 0.01 0.34 ± 0.82 0.111
Dihydroprogesterone 3.07 ± 1.54 0.25 ± 0.00*# 1.00 ± 1.28* 0.001
Isopregnanolone 0.11 ± 0.03 0.10 ± 0.00# 0.32 ± 0.63 0.531
Tetrahydroprogesterone 0.11 ± 0.03 0.25 ± 0.29 0.10 ± 0.00# 0.275
Dehydroepiandrosterone 0.29 ± 0.08 0.33 ± 0.05 0.51 ± 0.58 0.217
Testosterone 0.23 ± 0.85 2.53 ± 2.35* 1.26 ± 1.48 0.028
Dihydrotestosterone 0.15 ± 0.12 0.05 ± 0.01* 0.49 ± 1.13 0.029
3α-Diol 0.05 ± 0.00# 0.07 ± 0.04 0.64 ± 0.86 0.081
3β-Diol 0.05 ± 0.00# 0.05 ± 0.00# 0.25 ± 0.57 0.305
17β-Estradiol 0.4 ± 0.06 0.02 ± 0.00# 0.22 ± 0.56 0.676
Neuroactive steroid levels were previously reported {Melcangi, 2017 #2163}. Detection limit 
was 0.1 pg/µL for isopregnanolone and tetrahydroprogesterone, 0.05 pg/µL for 
progesterone, and 3β-Diol, 0.02 pg/µL for 17β-Estradiol. Data are expressed as pg/µL 
(mean±SD). Data were analysed by Kruskall-Wallis test followed by post-hoc Dunnet test (* 
vs. unmethylated controls, p<0.05). # denotes analytes for which the assay detection limit 
was used for the statistical analysis
Page 25 of 25 Accepted Manuscript published as EC-19-0199.R1. Accepted for publication: 04-Jul-2019
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 07/05/2019 08:07:46AM
via Univ Modena e Reggio Emilia
